PRTA Overview

Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.

Wall Street analysts forecast PRTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRTA is22.20 USD with a low forecast of 8.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Prothena Corporation PLC revenue for the last quarter amounts to 21.00K USD, decreased -99.01

Prothena Corporation PLC. EPS for the last quarter amounts to -0.40 USD, decreased -62.96

Prothena Corporation PLC (PRTA) has 67 emplpoyees as of April 04 2026.

Today PRTA has the market capitalization of 530.79M USD.